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Abstract Central role of astrocyte elevated gene-1 (AEG-
1) in regulating diverse aspects of hepatocellular carcinoma
(HCC) pathogenesis and association of its overexpression
with HCC progression has been demonstrated. The positive
regulatory regions of AEG-1 promoter contain several
putative transcription factor binding sites critical for basal
promoter activity. In this study, the aim was to explore the
association of AEG-1 promoter variant with HCC. In this
study, the human AEG-1 promoter including the region
-538 to -42 was explored in 53 HCC patients and 108
healthy controls. The polymerase chain reaction-sequenc-
ing method was used for investigating AEG-1 promoter
polymorphisms. A novel mutation in AEG-1 promoter in
human HCC patients at a potential AP-2 binding site was
explored. An A[C mutation was observed in -483 of
AEG-1 promoter in 4 out of 53 HCC patients but not in 108
control individuals. Sequencing data showed genetic vari-
ations in 11 HCC patients and 3 healthy controls. Among
them, one novel SNP was found in activator protein-1
(AP2), a transcription factor binding site (-483 A to C)
that may be associated with the susceptibility to HCC
(P = 0.012) but no associations were found for other
observed variations. This mutation could be tumor-specific.
AEG-1 promoter variant -483 A[C may be associated
with the susceptibility to HCC in Iranian population. To
our knowledge, this is the first study that has reported this
association with the susceptibility to HCC. Therefore,
further studies need to be conducted in larger sample sizes
and other populations to validate these findings.
Keywords Astrocyte elevated gene-1  Hepatocelluar
carcinoma  Promoter
Introduction
Cancer is the third most common cause of death in Iran,
and annually 30,000 of Iranian die due to cancer [1].
Hepatocellular carcinoma (HCC) is a highly aggressive
vascular cancer characterized by divers’ etiology, activa-
tion of multiple signal transduction pathway, and various
gene mutation [2]. HCC is the sixth most prevalent cancer
worldwide. Furthermore, due to its poor prognosis, it is
also the fourth leading cause of death related to cancer
[3]. The annual incidence of HCC has been estimated to
be high in Africa (24/100,000) and eastern areas of Asia
(35/100,000), whereas its incidence is low in North
America, Western Europe, and the Middle East (3–4/
100,000) [3]. A variety of important risk factors for HCC
development has been identified. It includes the hepatitis
B carrier state, chronic hepatitis C virus (HCV) infection,
hereditary hemochromatosis, and cirrhosis of almost any
cause [4].
Astrocyte elevated gene-1 (AEG-1, also known as
MTDH, and Lyric) was first reported in 2002 as a novel
late response gene following HIV-1 infection or treatment
with recombinant HIV-1 envelope glycoprotein (gp120)
[5]. The full-length cDNA has subsequently been inde-
pendently cloned by four different groups of investigators
[6–9]. Expression analysis revealed that AEG1 expression
is significantly higher in melanoma, breast and prostate
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cancers [6], ductal and lobular carcinomas [10], and
malignant glioma cell lines compared with their normal
counterparts [6]. AEG-1 is overexpressed in [90 % of
human HCC patients and plays a significant role in medi-
ating aggressive progression of HCC [2]. In addition, it
plays a significant role in invasion, metastasis, angiogen-
esis, apoptosis inhibition [11], and chemoresistance, all
important hallmarks of an aggressive cancer. AEG-1 is also
implicated in diverse physiological and pathological pro-
cesses, such as development, inflammation, neurodegen-
eration, migraine, and Huntington’s disease [12]. Lee et al.
[13] identified the transcription factors binding to the
-459/-301 region by using electrophoretic mobility shift
assays (EMSA). They also confirmed that the human
AEG-1 promoter has positive (-459/-302) and negative
(-738/-460) regulatory regions. Although the positive
regulatory region contains several putative transcription
factor binding sites critical for basal promoter activity,
such as Sp1, E-box element, CREB, and Ets-2, their data
indicate that two E-box elements in this region are func-
tional and important for both basal and Ras-induced pro-
moter activity. In this study, the aim was to investigate the
association between the AEG-1-positive region promoter
variant in HCC patients that can be a reason to increased
expression of this gene. To our knowledge, this region has
not been previously tested in the HCC patients.
Subjects and method
In this study, the sample size for the patient and control
groups, respectively, 53 and 108 was calculated [14]. The
HCC patients were recruited from the Mazandaran, Tehran,
Shiraz, Esfahan, Sistan and Baluchestan, and Gorgan
Provence, Iran hospitals. The controls, recruited from the
Mazandaran, were age-matched with the case population.
HCC patient diagnosis was based on the standard criteria
(pathologic, histopathology, and demographic). In this
study, the patient average age of 59 years and a control
group, 57.5 were calculated. In patients with HCC, 47 %
were female and 53 % male and in control 50 % were
female and 50 % male subjects. All experiments were
performed under the approval of the Institutional Review
Board, University of Zabol. Written informed consent was
obtained from each subject.
DNA extraction
Genomic DNA was extracted from paraffin-embedded
tissues from the patients, using the phenol/chloroform
procedure, and from blood cells of the controls, using the
boiling procedure. DNA and the purity of each sample
were measured by Picodrop. DNA samples were routinely
stored at -20 C [15].
Sequencing analysis of human AEG-1 gene
The AEG-1 gene promoter (accretion number: AF411226)
was sequenced to investigate genetic variants in DNA sam-
ples from the 53 cases and 108 controls. The distribution of
promoter variants was determined by polymerase chain
reaction (PCR)-sequencing method. Briefly, the region was
amplified by the following primers: Forward 50-GAAGGCG
TCCACCAATTAAC-30; Reverse 50-CGGAGACGCAGTG
GAATAGT-30. In this study, we propose an improved PCR
method to be used for the successful amplification of the
AEG-1 gene promoter region that exhibits [70 % G ? C
content in a sequence of approximately 496 bp using touch-
down PCR and co-activator dimethyl sulfoxide (DMSO). The
touchdown PCR was carried out on corbett Thermal Cycler
using the following conditions: an initial denaturation at
96 C for 7 min, followed by 16 cycles of 94 C for 1 min,
60 C (0.5 C decrease per cycle) for 45 s, 72 C for 1 min,
then another 15 cycles of 94 C for 1 min, 52 C for 45 s,
72 C for 1 min, and a final extension step at 72 C for 7 min.
The PCR products were separated on 2 % agarose gels in Tris
base EDTA (TBE) buffer stained with SYBR Safe DNA Gel
Stain and visualized by Gel Doc Imaging System. All
sequencing data were produced by the Genomic Analysis
Facility (Puia Gostar Gene, Tehran, Iran) Chromas software.
Statistical analysis
Data were analyzed for statistical significance using Fisher’s
exact test followed by SPSS statistical software (version 16,
SPSS, Chicago, IL, USA). P \ 0.05 was considered
significant.
Results
A study was undertaken, comprising 53 HCC patients and 108
controls, all over 57/5 years of age. Comparative analysis
between the ratio of absorbance at wavelengths of 260 and
280 nm was performed. Average ratios obtained in the range
of 1.7 were suitable for DNA (Tables 1, 2).
Table 1 Spectroscopy of DNA
extracted from blood samples
randomly
260/280
(OD)
Density
(ng/ll)
Sample
1.9 440.1 C001
1.6 552.2 C027
1.72 349.4 C094
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To ensure more, it was followed by electrophoresis
(Fig. 1).
The AEG-1 gene promoter by touchdown PCR DNA
fragment was amplified. All samples have a clear runway
suitable for sequencing (no non-specific bands and primer
dimer, respectively). Samples were electrophoresed in
front of 100-bp size marker.
In the following, sequences obtained for genotyping
were compared with the standard sequence. The results
showed three single-nucleotide changes in healthy indi-
viduals and 11 in patients, respectively (Table 3). Nucle-
otide changes in the patients (Table 4) are shown.
Three nucleotide variants of AEG-1 promoter [-432
(A[T), -338 (C[G), -458 (A[C)] were detected in the
control group (Table 5).
Six nucleotide variants [-449 (C[T), -351 (T[C),
-234 (C[G), -412 (C[A), -494 (A[T), -376 (C[A)],
one deletion (-469; A), and one novel SNP (-483; A[C)
were discovered in the affected HCC cancer patients. The
variants appear to gather at -300 to -500 bp of AEG-1
gene promoter. This novel SNP displayed in the central
part of the AP-2 transcription factor binding site in four
case groups, but not in the control group. Data obtained
from sequencing were analyzed (Fig. 2). In the following,
the results of the BLAST sequence of AEG-1 gene pro-
moter sequences of patients in the NCBI are shown.
Fig. 1 Genomic DNA was electrophoresed on 1 % agarose gel
Table 3 Percentage types of nucleotide changes between healthy
subjects and patients
Single-nucleotide
percentage change
Deletion percentage
single nucleotide
867.18 3.773 Patients
851.1 0.925 Healthy subjects
Table 4 Nucleotide changes in patients
Type of change Mutant
genotype
Wild
genotype
Sample code
Base displacement CCCAC CCAAC P052/P007/P049/P008
Base displacement ACTGC ACCGC P039
Deletion TT-AC TTAAC P050
Deletion GA-CA GACCA P017
Base displacement
Base displacement
CGTCC
CGGCG
CGCCC
CGCCG
P028
Base displacement ACACC ACCCC P012
Base displacement GTTAC GTAAC P023
Base displacement CCAAT CCACT P034
Table 5 Nucleotide changes in healthy subjects
Type of change Mutant
genotype
Wild
genotype
Sample
code
Base displacement GACCC GAACC C047
Base displacement ACTCG ACACG C013
Deletion CGTGGA CGT-GA C100
Table 2 Spectroscopy of DNA
extracted from tissue samples
randomly
260/280
(OD)
Density
(ng/ll)
Sample
1.5 567.21 P007
1.6 472.2 P024
1.53 552.4 P010
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BLAST results of the sequences obtained from
sequencing AEG-1 gene promoter in healthy subjects with
reference sequences in the NCBI are shown:
For statistical comparison of mutation distribution
between patients and healthy controls, Fisher’s exact test
was used. The results showed a statistically significant
difference in -483 (A to C) mutation frequency that may
be associated with the susceptibility to HCC (P = 0.012)
but no associations were found for other observed varia-
tions (Figs. 3, 4).
Discussion
The present manuscript describes findings that are highly
significant and relevant in the context of HCC. In this
study, the aim was to explore the association of AEG-1
promoter variant with HCC. Our investigations indicate
that there is a statistically significant association between
one novel AEG-1 promoter SNP (untitled) and HCC can-
cer. There is not any investigation about AP-2 function in
HCC. SNPs in the promoter region of a gene can poten-
tially alter the affinity of interactions between DNA and
nuclear proteins and, in turn, affect the efficiency of tran-
scription [16]. Previous studies have demonstrated that
many oncogenes and tumor suppressor genes are directly or
indirectly associated with the development and progression
of cancer. Genetic variation in these genes from the per-
spective of cancer molecular diagnosis, monitoring, and
treatment is necessary [17]. One of the most important
oncogene of the malignant progression of HCC is the
AEG-1 [18]. Genetic variation in the gene exons and
introns in breast cancer by Liu and colleagues was per-
formed using direct sequencing, and the possibility of
Fig. 2 Sequencing chromatogram results of Novel SNP (A[C) in
AEG-1 promoter
DNA ladder
100bp
496b
Fig. 3 Bands observed after electrophoresis of PCR product of AEG-1
(bond length 496 bp). Line 1–6: patients; line 7–12: non-patients
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multiple mutations associated with breast cancer was
reported. Three new mutations associated with this type of
cancer in exons 6 and 7 and intron 7 were found [19]. AEG-
1 proto-oncogene overexpression in patients with HCC has
been proven in many studies to be due to the amplified
chromosomal location of the gene and promoter over
activity [18]. AEG-1 is a key contributor to the carcino-
genic process in diverse organs and this protein expression
is elevated in advanced stages of many cancers, which
correlates with poor survival [15]. Promoter sequence of
human genes has a high CG content, and since the
sequence of this study is a promoter sequence, replication
using PCR techniques is difficult because, on the one hand,
due to the strength of the gangs that exist in this, sequence
denaturation is difficult, and on the other hand, at annealing
stage before the primer binding to the template DNA,
secondary structures formed by self-complementary and
thus prevent primer binding and reduced yields. To resolve
this problem, the co-activator including betaine, glycerol,
Tween20, and DMSO was used and only the concentration
of 5.6 % DMSO could help replication desired sequence.
Touchdown PCR technique was used to enhance specific
product, and the products were sequenced. The results of
healthy individuals showed a single-nucleotide deletion at
C100 sample and 2 nucleotide changes at C13 and C47
samples (Table 5) after the sequence of binding sites of
transcription factors and the transcription start site,
respectively. Four mutations in the transcription factor AP-
2 at P008, P052, P007, and P049 samples and different
single-nucleotide changes in the sequence of the binding
sites of transcription factors in samples of P050, P039,
P017, P012, P028, P023, and P034 patients (Table 4)
occurred. Only three of the 103 healthy individual’s
nucleotides have changed (2.8 %) while the 11 nucleotide
changes were observed in the 53 patients studied, which is
equal to 20.8 %. Nucleotide percentage changes represent
a tenfold increase in the DNA changes of tumor tissues due
to the development of tumors in cancer tissues involves
genetic changes [20]. Given that AEG-1 is associated with
several signaling pathways and can be involved in tumor-
igenesis [18], so nucleotide changes in the promoter can be
involved in the cell. The mutation is occurred in proto-
oncogene, regardless of the presence or absence of growth
signal divided into permanent and continuous induction of
cell growth that can lead to undesirable and unwanted
cancer cells [20]. AEG-1 is a proto-oncogene in regulating
the proliferation of normal cells in the presence of appro-
priate growth signals. Since a mutation alone is sufficient
to activate a proto-oncogene, if one of the two copies of the
cell is activated makes cell new behavior and is likely to
grow further [21]. Existence of several mutations in the
AEG-1 gene promoter in healthy individuals with a mean
age of 63.5 years old who were not associated with
malignancy can be linked with the accumulation of muta-
tions that increase the aging effects of these mutations with
future onset of malignancy [22]. Genetic instability could
be an advantage because the cancer is to advance the
process that led to the accumulation of carcinogenic
mutations is faster. We observed these changes in AEG-1
gene promoter in the cancer samples that we studied. Most
of these mutations were observed after the positive and
negative regulatory sequence promoter and near the tran-
scription start site were seen. About 36.36 % of the
mutations (4/11) at the binding site of the transcription
factor AP-2 (-479 to -483) CCAACGCC sequence were
observed. In the position of (-483 bp), adenine to cytosine
(A[C) was changed. Comparing the distribution of muta-
tions in the AP-2 binding site in both patients and control
group showed a statistically significant difference between
the two groups (P \ 0.012), and this change could be
linked with HCC. The transcription factor AP-2 family
consists of AP-2b, AP-2c, AP-2d, and AP-2e [23]. AP-2
activity in various cancers has been demonstrated in many
studies, including its role in apoptosis, cell growth, and
differentiation [24] and can also be regarded as a key factor
in the regulation of tumor growth [25]. Interestingly, AP-2
in some cancer acts as a tumor suppressor gene while in
others it acts as an oncogene. On the other hand, AP-2
appears to be involved in growth control and can cause
direct inhibition of the activation of the cell cycle with
activation of P21 [26]. AP-2 is a tumor suppressor and its
loss is an important factor and step in the development of
melanoma [27] and glioma [26]. On the other hand, AP-2
in mice with suppressed immune system can cause
enhancing apoptosis in many tissues [28]. Direct correla-
tion exists between ERBB2/HER2/NEU proto-oncogene
Fig. 4 Charts mutation rates between the patients and healthy
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expression and AP-2 in breast cancer, and over ErbB2
expression is intended as a marker for the detection of
cancer and resistance to chemotherapy [29]. Analysis of the
AP-2 gene promoter demonstrates that AP-2 could poten-
tially act as an activator [30]. In addition, AP-2 can directly
increase VEGF transcription involved in angiogenesis and
metastasis [31]. Another study demonstrated that AP-2 will
be present in many pancreatic cancer cell lines in the
nucleus with its mRNA various isoforms [25]. Due to the
lack of study on relationship between HCC and transcrip-
tion factor AP-2, and since AEG-1 increased expression in
HCC has been confirmed [18], so the observed nucleotide
changes (A[C) at the junction of the transcription factor
AP-2 binding sequences by creating suitable as a tran-
scriptional activator function and overexpression of AEG-1
is caused. On the other hand, as noted in the text, if the
AP-2 in breast cancer acts as a suppressor, this binding site
change can cause a lack of proper connectivity suppressor
factor of AP-2 and could not play correctly his job as AEG-
1 expression suppressor. Although not required for this
study, it would be worthwhile to see whether this particular
mutation affects promoter function in in vitro assays.
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